港股異動 | 藥明生物升超7%創新高,預計上半年淨利潤同比增長超過58%
uSMART友信智投7月29日消息,週三港股,藥明生物高開高走,截至9:42分,藥明生物升7.07%,報160.6港元,市中最高觸及162港元,創上市以來新高。
藥明生物今日早間發佈公告,集團預期截至2020年6月30日止6個月所取得的歸屬於公司權益股東的利潤相比於去年同期增長58%以上。
該增長主要是由於:(i)集團迅速開展有效的業務連續性計畫,以儘量降低COVID-19疫情對其業務及運營帶來的影響;(ii)集團研發管線引入更多客戶專案,支援全球客戶加快COVID-19相關潛在療法的開發及生產;(iii)集團現有產能利用率的提升,部分被新生產基地產能爬坡及隨著集團業務增長而增加的行政開支所抵銷;及(iv)投資、外匯、往年退稅收益及錄得其他營業外收入。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.